98%
921
2 minutes
20
Parotid gland (PG) shrinkage and neck volume reduction during radiotherapy of head and neck (H&N) cancer patients is a clinical issue that has prompted interest in adaptive radiotherapy (ART). This study focuses on the difference between planned dose and delivered dose and the possible effects of an efficient replanning strategy during the course of treatment. Six patients with H&N cancer treated by tomotherapy were retrospectively enrolled. Thirty daily dose distributions (D) were calculated on pretreatment megavoltage computed tomography (MVCT) scans. Deformable Image Registration which matched daily MVCT with treatment planning kilovoltage computed tomography was performed. Using the resulting deformation vector field, all daily D were deformed to the planning kilovoltage computed tomography and resulting doses were accumulated voxel per voxel. Cumulative D was compared to planned dose distribution performing γ-analysis (2 mm, 2% of 2.2 Gy). Two single-intervention ART strategies were executed on the 18th fraction whose previous data had suggested to be a suitable timepoint for a single replanning intervention: (1) replanning on the original target and deformed organ at risks (OARs) (a "safer" approach regarding tumor coverage) and (2) replanning on both deformed target and deformed OARs. D showed differences between planned and delivered doses (3D-γ 2mm/2%-passing rate = 85 ± 1%, p < 0.001). Voxel by voxel dose accumulation showed an increase in average dose of warped PG of 3.0 Gy ± 3.3 Gy. With ART the average dose of warped PG decreased by 3.2 Gy ± 1.7 Gy in comparison to delivered dose without replanning when both target and OARs were deformed. Average dose of warped PG decreased by 2.0 Gy ± 1.4 Gy when only OARs were deformed. Anatomical variations lead to increased doses to PGs. Efficient single-intervention ART-strategies with replanning on the 18th MVCT result a reduced PG dose. A strategy with deformation of both target and OAR resulted in the lowest PG dose, while formally maintaining PTV coverage. Deformation of only OAR nevertheless reduces PG dose and has less uncertainties regarding PTV coverage.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.meddos.2019.02.002 | DOI Listing |
Acta Vet Hung
September 2025
4Department of Internal Medicine, University of Veterinary Medicine Budapest, István Street 2, 1078 Budapest, Hungary.
The low dose dexamethasone stimulation test (LDDST) is routinely used in canine medicine but in the few cases in guinea pigs diagnosed with hypercortisolism, the adrenocorticotropic hormone (ACTH) stimulation test was used. The objective of the authors was to conduct a pilot study and find out if the standard test used in dogs can be used in this species.A 4-year-old intact female hairless guinea pig showed bilaterally enlarged adrenal glands and high cortisol levels.
View Article and Find Full Text PDFCell Mol Biol (Noisy-le-grand)
September 2025
Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Despite significant advancements in the treatment of non-small cell lung cancer (NSCLC) using conventional therapeutic methods, drug resistance remains a major factor contributing to disease recurrence. In this study, we aimed to explore the potential benefits of combining PI3K inhibition with Cisplatin in the context of NSCLC-derived A549 cells. Human non-small cell lung cancer A549 cells were cultured and treated with BKM120, cisplatin, or their combination.
View Article and Find Full Text PDFIndian Pediatr
September 2025
Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
Objective: To determine the cyclosporine trough (C) and two-hour post-dose concentrations (C) in children with nephrotic syndrome (NS) and study the factors influencing them.
Methods: In this ambispective cohort study, children with NS (including frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome) on cyclosporine therapy were enrolled. Clinical and laboratory data were recorded.
Target Oncol
September 2025
Department of Drug Design and Pharmacology, University of Copenhagen, Copenhagen, Denmark.
Background: Population pharmacokinetic models can potentially provide suggestions for an initial dose and the magnitude of dose adjustment during therapeutic drug monitoring procedures of imatinib. Several population pharmacokinetic models for imatinib have been developed over the last two decades. However, their predictive performance is still unknown when extrapolated to different populations, especially children.
View Article and Find Full Text PDFAdv Ther
September 2025
Centre d'Ophtalmologie Visis, 66000, Perpignan, France.
Introduction: Glaucoma treatment predominantly involves the use of topical anti-glaucoma eye drops, with patient adherence influenced by individual preferences. This study aimed to assess these preferences and highlight the importance of personalized treatment approaches among ophthalmologists.
Methods: This French multicenter, cross-sectional study involved 21 ophthalmologists-members of the Board of Directors of the French Society of Glaucoma-from both public and private practices, who distributed a standardized questionnaire to their patients with glaucoma.